Overview

Update
Total Equity Funding
$83.8M in 5 Rounds from 5 Investors
Most Recent Funding
$38M Series C on January 27, 2016
Headquarters:
Watertown, MA
Description:
Tarveda Therapeutics takes a novel approach to cancer treatment
Founders:
,
Categories:
Therapeutics, Health Care, Health Diagnostics, Medical
Website:
http://www.tarveda.com/

Company Details

Update

Formerly Known as Blend Therapeutics. Tarveda creates Pentarins that are targeted miniature drug conjugates that remain miniature by design to overcome the challenges that limit the efficacy of larger antibody drug conjugates in use and development today. Specifically, our Pentarins are designed to penetrate deep into solid tumors, target cancer cells selectively, drive sufficient accumulation of the drug at the site of the tumor, deliver effective, potent payloads into the targeted cancer cells, and cause cancer cell death deep within the solid tumors.

Tarveda’s innovative cancer therapies are based on the company’s Pentarin platform, through which we create our novel, miniaturized biologic drug conjugates. With our platform capabilities and cancer drug development expertise, our team creates Pentarins comprised of an innovative targeting ligand, linked to a potent payload, designed to penetrate deep into solid tumors and cause cancer cell death.

Funding Rounds (5) - $83.8M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jan, 2016$38M / Series C2
Jan, 2015$21M / Series B4
Mar, 2014$1M / Venture0
Dec, 2013$21M / Series B3
Jan, 2012$2.8M / Series A3

Current Team (6)

Update

Offices/Locations (1)

Update
  • Office

    134 Coolidge Avenue

    Watertown, MA 02472

    USA

Past Team (3)

Update

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos